The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Cited by
Phenomenology of the Initial Burst Release of Drugs from PLGA Microparticles
Yoo, J., & Won, Y.-Y. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01228 · Cited by 392
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Clinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250
“1171 the mean peak steady-state peak concentrations of the active moiety were 25-32 % lower with LAI than oral RSP, and their fluctuations were 32-42 % lower (Eerdekens et al., 2004; Nesvag et al., 2006).”
BackgroundCorrell, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205
A Visual Guide to Expected Blood Levels of Long-Acting Injectable Risperidone in Clinical Practice
WILSON, W. H. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200411000-00009 · Cited by 180
BURTON, S. C. (2005) · Journal of Psychiatric Practice · doi:10.1097/00131746-200511000-00003 · Cited by 68
Heres, S., Reichhart, T., Hamann, J., Mendel, R., Leucht, S., & Kissling, W. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2009.12.020 · Cited by 64
Kimura, H., Kanahara, N., Komatsu, N., Ishige, M., Muneoka, K., Yoshimura, M., Yamanaka, H., Suzuki, T., Komatsu, H., Sasaki, T., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.02.022 · Cited by 55
Gharabawi, G. M., Gearhart, N. C., Lasser, R. A., Mahmoud, R. A., Zhu, Y., Mannaert, E., Naessens, I., Bossie, C. A., Kujawa, M., & Simpson, G. M. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-3 · Cited by 27
“Further, the percentage fluctuation and the Cmax-toCmin ratios were approximately 3 times higher after monthly injections than after biweekly injections;[2] however, the average exposure to risperidone plus 9hydroxyrisperidone was comparable between oncemonthly dosing and historical data from biweekly dosing.”
InfluentialSelf-citationKimura, H., Kanahara, N., Sasaki, T., Komatsu, N., Ishige, M., Muneoka, K., Ino, H., Yoshimura, K., Yamanaka, H., Suzuki, T., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116655978 · Cited by 26
“Generally, agents with a long halflife like a long-acting injectable (LAI) show less fluctuation between peak and trough plasma levels, compared to the oral type of the same agent, when patients are given dosages leading to similar DRD2 occupancy rates (Eerdenkens et al., 2004).”
BackgroundThyssen, A., Rusch, S., Herben, V., Quiroz, J., & Mannaert, E. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009355156 · Cited by 26
Self-citationLaffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.366 · Cited by 26
Metadata
- Authors
- Eerdekens, M., Van Hove, I., Remmerie, B., & Mannaert, E.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 70
- Issue
- 1
- Pages
- 91-100
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W1972852190
- Cited by
- 161
- References
- 1
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.